Advanced Enzymes Says SciTech Margin Gain Is Broad-Based
Key highlights
- SciTech revenue rose by Rs 4.9 crore to Rs 23.4 crore in Q2 FY27 from Rs 18.5 crore in Q2 FY26.
- SciTech EBITDA increased to Rs 6.1 crore in Q2 FY27 from Rs 3.3 crore a year earlier.
- SciTech H1 FY27 revenue was Rs 43.4 crore, compared with Rs 33 crore in H1 FY26.
- Advanced Enzymes said its top 10 customers accounted for about 26% of consolidated Q2 FY27 revenue, versus 27% a year earlier.
powered by IRIS

Advanced Enzyme Technologies Limited said SciTech’s Q2 FY27 EBITDA rose to Rs 6.1 crore from Rs 3.3 crore as revenue reached Rs 23.4 crore, with management attributing the margin improvement to a broader customer base, additional shifts, better capacity utilisation and research and development products reaching the market.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
What drove SciTech’s Q2 FY27 expansion?
SciTech’s expansion was broad-based rather than driven by a single customer or one-off order, management said on the November 3, 2026 earnings call. In response to an analyst, Advanced Enzymes said its customer base had widened and that multiple research and development, or R&D, programmes at SciTech were beginning to pay off. Management did not disclose SciTech’s number of customers, its largest customer or revenue from its leading product.
Additional shift work was the operational mechanism behind the higher output, according to management. Advanced Enzymes said extra shifts increased production capacity and that fuller capacity use improved efficiencies. SciTech revenue increased by Rs 4.9 crore year on year to Rs 23.4 crore in Q2 FY27. The separately reported Specialized Manufacturing segment generated Rs 23.1 crore, up 25% year on year and 15% sequentially; management did not reconcile the Rs 0.3 crore difference between the segment and SciTech figures.
The Q2 result extended a stronger first half for the business. SciTech revenue was Rs 43.4 crore in H1 FY27, compared with Rs 33 crore in H1 FY26, a reported 32% increase. Specialized Manufacturing accounted for about 11% of Advanced Enzymes’ consolidated Q2 revenue, compared with Human Healthcare revenue of Rs 128.5 crore. The comparison places SciTech’s growth in a smaller business line than the company’s largest segment.
How much did SciTech profitability change?
SciTech profitability increased materially in Q2 FY27, with EBITDA rising to Rs 6.1 crore from Rs 3.3 crore and profit after tax, or PAT, rising to Rs 3.6 crore from Rs 1.5 crore in Q2 FY26. Based on the disclosed revenue and EBITDA figures, the implied EBITDA margin was about 26.1% in Q2 FY27, versus about 17.8% a year earlier. Advanced Enzymes did not separately state a SciTech margin percentage.
The H1 comparison shows a similar shift from a lower prior-year base. SciTech EBITDA rose to Rs 9.2 crore in H1 FY27 from Rs 3.8 crore in H1 FY26, while PAT increased to Rs 4.9 crore from Rs 0.8 crore. The implied H1 EBITDA margin increased to about 21.2% from about 11.5%, based on revenue of Rs 43.4 crore and Rs 33 crore respectively.
SciTech’s EBITDA growth exceeded the consolidated rate in the quarter, although Advanced Enzymes did not quantify its contribution to group profitability. Consolidated Q2 FY27 EBITDA rose 20% to Rs 72.1 crore on revenue of Rs 214.5 crore, producing a disclosed EBITDA margin of 34%, compared with 33% in Q2 FY26. SciTech EBITDA increased by Rs 2.8 crore over the same period, while the company attributed its own improvement to utilisation and shift-related efficiencies.
Got a follow-up? Ask IRIS
Is SciTech growth dependent on a few customers?
Advanced Enzymes said SciTech’s traction is broad-based and that a wider customer base is part of the current growth mechanism. Management also cited new R&D outputs and additional shifts when asked whether the business was scaling through a few customers or broader adoption. It declined to provide revenue from the top product, leaving the contribution of individual products, customers, end markets and geographies undisclosed.
Group-level concentration data shows a small reduction, but it is not a SciTech-only measure. Advanced Enzymes said its top 10 customers accounted for about 26% of consolidated Q2 FY27 revenue, against 27% in Q2 FY26. In H1 FY27, the top 10 represented 22% of revenue, compared with 23% a year earlier. Those figures cannot establish the concentration of Specialized Manufacturing sales.
Management did not characterise the Q2 outcome as a one-time event, though it cautioned investors not to judge the business on a single quarter. Specialized Manufacturing revenue grew 32% in H1 FY27, against 10% growth in consolidated revenue to Rs 406.2 crore. That half-year comparison supports management’s statement that momentum extends beyond one quarter, but the call provided no SciTech-specific growth target for the rest of FY27.
Which products and R&D work support SciTech?
SciTech’s Specialized Manufacturing activity includes effervescent tablets and orally disintegrating, or OD, tablets for pharmaceutical, cosmetics, nutraceutical and animal-feed applications. Management cited different delivery systems for animal feed as an example of the R&D work undertaken in this business. It did not disclose how the Rs 23.4 crore of Q2 FY27 SciTech revenue was divided among those product formats or end markets.
Advanced Enzymes increased consolidated R&D spending to Rs 9 crore in Q2 FY27 from Rs 8.6 crore in Q2 FY26, and to Rs 21.6 crore in H1 FY27 from Rs 16.6 crore a year earlier. After intercompany eliminations, management said R&D expense was 4.3% of Q2 revenue, compared with 3% a year earlier. It linked SciTech’s traction to R&D programmes paying off but did not allocate group R&D expenditure to SciTech.
Management estimated that new products contributed roughly 7% to 8% of company revenue, while describing that figure as approximate. It said Advanced Enzymes does not bifurcate or report sales from new products. As a result, the call does not show whether new SciTech products gained share during FY27 or how much of the Rs 4.9 crore increase in Q2 SciTech revenue came from existing products.
Conclusion
SciTech’s Q2 FY27 performance combined higher revenue with faster EBITDA and PAT growth, and management linked that change to several stated mechanisms rather than a single account: a broader customer base, added shifts, better capacity utilisation and R&D-led delivery systems. The H1 FY27 figures, including revenue of Rs 43.4 crore and EBITDA of Rs 9.2 crore, provide a longer-period indication of the same direction.
The next results to watch are the remaining FY27 quarters, particularly whether Specialized Manufacturing sustains revenue growth while R&D programmes convert into sales. Management said Advanced Enzymes is aiming for lower-double-digit revenue growth and maintained an overall EBITDA-margin guideline of 30% to 32%, but gave no separate SciTech target. Further disclosure on the difference between Q2 SciTech revenue of Rs 23.4 crore and Specialized Manufacturing revenue of Rs 23.1 crore would also clarify the reported business measures.


